Overview
Novartis is a Basel holding company that develops, manufactures and markets health-care products, with a portfolio concentrated on innovative prescription medicines in oncology, immunology, neuroscience and cardiovascular disease.[2] Forbes records sales of US$54.4bn, up 8.2% on the prior-year figure, and profit of US$13.6bn, a margin of almost 25%.[2] Sandoz, a generics company headquartered in Switzerland, appears separately in the Forbes data with sales of US$11.1bn and is not part of Novartis’s figures.[2] Novartis remains in eighth position, unchanged from the prior-year comparison. Forbes gives the founding date as 29 February 1996, the date of the merger that created the group, and puts its workforce at 75,267.[2]
Novartis strengths and limitations
Strengths
- Profit margin near 25%
- Concentrated on innovative medicines
- Stable position in the ranking
Limitations
- Smaller than Roche despite similar profile
- Sales growth below AstraZeneca and AbbVie
- Several key brands face patent expiries
Appears in
Novartis peers and competitors
Companies ranked in the same lists as Novartis.
Roche Group- Glencore plc
- Amgen
Pfizer- AbbVie
AstraZeneca PLC
Bayer AG
Novo Nordisk
Sanofi- Bristol Myers Squibb
GSK plc
Gilead Sciences
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.